Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. J Eur Acad Dermatol Venereol 2017.
In,1 there was an error in Figure 5. The numbers of ADA‐negative and ADA‐positive patients at retreatment weeks 0 through 24 in the legend below the graph were inverted and should have read:
Reference
- 1. Blauvelt A, Papp KA, Sofen H et al Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 1004–1013. [DOI] [PMC free article] [PubMed] [Google Scholar]